385
Participants
Start Date
September 4, 2014
Primary Completion Date
March 31, 2021
Study Completion Date
March 31, 2021
Zanubrutinib
Oral administration by capsule
Peter MacCallum Cancer Centre, East Melbourne, Parkville
University of Michigan, Ann Arbor
Mayo Clinic, Rochester
M.D. Anderson Cancer Center, Houston
Banner MD Anderson Cancer Centre, Gilbert
Concord Repatriation General Hospital, Concord
St George Hospital, Sydney
Westmead Hospital, Westmead
Princess Alexandra Hospital, Brisbane
Royal Hobart Hospital, Hobart
Monash Health, Clayton
Austin Health, Heidelberg
St Vincent's Hospital, Melbourne
Melbourne Health, Parkville
Sir Charles Gairdner Hospital, Nedlands
Policlinico S.Orsola Malpighi, AOU di Bologna, Bologna
Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milan
North Shore Hospital, Auckland
Dong-A University Medical Centre, Busan
Inje University Busan Paik Hospital, Busan
National Cancer Center, Goyang-si
Samsung Medical Center, Seoul
Derriford Hospital, Plymouth
Lead Sponsor
BeiGene
INDUSTRY